Litcius/Paper detail

745MO Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study

Kathleen N. Moore, Alexander Philipovskiy, Kenichi Harano, Brian I. Rini, Kazuki Sudo, Shigehisa Kitano, David R. Spigel, W. Marston Linehan, Mondira Kundu, Amine Bensmaine, Yusuke Myobatake, E.P. Hamilton

2023Annals of Oncology21 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTolerabilityInternal medicineAdverse effectTaxaneOvarian cancerGastroenterologyPhases of clinical researchOncologyCancerChemotherapyBreast cancerHER2/EGFR in Cancer ResearchOvarian cancer diagnosis and treatmentMonoclonal and Polyclonal Antibodies Research
745MO Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study | Litcius